Safety and cardiovascular effects of mineralocorticoid receptor antagonists for patients receiving hemodialysis: a systematic review and meta-analysis

References

• Foley RN. Clinical epidemiology of cardiovascular disease in chronic kidney disease. J Renal Care. 2010;36:4–8.
   PubMedGoogle Scholar
• Collins AJ, Foley RN, Gilbertson DT, Chen SC. United States Renal Data System public health surveillance of chronic kidney disease and end-stage renal disease. Kidney Int Suppl. 2015;5:2–7.
   PubMed Web of Science ®Google Scholar
• Saran R, Li Y, Robinson B, et al. US Renal Data System 2014 Annual Data Report: Epidemiology of kidney disease in the United States. Am J Kidney Dis. 2015;65:A7.
   Web of Science ®Google Scholar
• Sinha AD, Agarwal R. Peridialytic, intradialytic, and interdialytic blood pressure measurement in hemodialysis patients. Am J Kidney Dis. 2009;54:788–791.
   PubMed Web of Science ®Google Scholar
• Zoccali C, Benedetto FA, Tripepi G, Mallamaci F. Cardiac consequences of hypertension in hemodialysis patients. Semin Dial. 2004;17:299–303.
   PubMed Web of Science ®Google Scholar
• Charytan D. Is left ventricular hypertrophy a modifiable risk factor in end-stage renal disease. Curr Opin Nephrol Hypertens. 2014;23:578–585.
   PubMed Web of Science ®Google Scholar
• K/DOQI Workgroup: K/DOQI clinical practice guidelines for cardiovascular disease in dialysis patients. Am J Kidney Dis. 2005;45:S1–153.
   Web of Science ®Google Scholar
• Funder JW. Minireview: Aldosterone and mineralocorticoid receptors: Past, present, and future. Endocrinology. 2010;151:5098–5102.
   PubMed Web of Science ®Google Scholar
• Funder JW. Aldosterone and mineralocorticoid receptors in the cardiovascular system. Prog Cardiovasc Dis. 2010;52:393–400.
   PubMed Web of Science ®Google Scholar
• Shavit L, Lifschitz MD, Epstein M. Aldosterone blockade and the mineralocorticoid receptor in the management of chronic kidney disease: Current concepts and emerging treatment paradigms. Kidney Int. 2012;81:955–968.
   PubMed Web of Science ®Google Scholar
• McLaughlin N, Gehr TW, Sica DA. Aldosterone-receptor antagonism and end-stage renal disease. Curr Hypertens Rep. 2004;6:327–330.
   PubMed Web of Science ®Google Scholar
• Agrawal S, Agrawal N, Garg J, Mohandas R, Gupta T, Segal M. Heart failure and chronic kidney disease: Should we use spironolactone? Am J Med Sci. 2015;350:147–151.
   PubMed Web of Science ®Google Scholar
• Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341:709–717.
   PubMed Web of Science ®Google Scholar
• Zannad F, McMurray JJ, Krum H, et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011;364:11–21.
   PubMed Web of Science ®Google Scholar
• Stewart Coats AJ, Shewan L. Eplerenone's role in the management of complex cardiovascular disorders. Int J Cardiol. 2015;200:1–2.
   PubMed Web of Science ®Google Scholar
• Pitt B, Rossignol P. Mineralocorticoid receptor antagonists in patients with end-stage renal disease on chronic hemodialysis. J Am Coll Cardiol. 2014;63:537–538.
   PubMed Web of Science ®Google Scholar
• Higgins JP, Altman DG, Gotzsche PC, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ (Clinical Research Ed). 2011;343:d5928.
   PubMed Web of Science ®Google Scholar
• Roseman M, Milette K, Bero LA, et al. Reporting of conflicts of interest in meta-analyses of trials of pharmacological treatments. JAMA. 2011;305:1008–1017.
   PubMed Web of Science ®Google Scholar
• Buljan M, Nemet D, Golubic-Cepulic B, Bicanic G, Tripkovic B, Delimar D. Two different dosing regimens of human recombinant erythropoietin beta during preoperative autologous blood donation in patients having hip arthroplasty. Int Orthopaed (SICOT). 2012;36:703–709.
   PubMed Web of Science ®Google Scholar
• Kikuchi H, Tan A, Nonaka T, Shimada W, Tanaka S. Comparison of intravenous and subcutaneous erythropoietin therapy for preoperative acquisition of blood for autologous transfusion in patients undergoing total arthroplasty. J Orthop Sci. 1997;2:84–87.
   Google Scholar
• Matsumoto Y, Mori Y, Kageyama S, et al. Spironolactone reduces cardiovascular and cerebrovascular morbidity and mortality in hemodialysis patients. J Am Coll Cardiol. 2014;63:528–536.
   PubMed Web of Science ®Google Scholar
• Gross E, Rothstein M, Dombek S, Juknis HI. Effect of spironolactone on blood pressure and the renin–angiotensin–aldosterone system in oligo-anuric hemodialysis patients. Am J Kidney Dis. 2005;46:94–101.
   PubMed Web of Science ®Google Scholar
• Taheri S, Mortazavi M, Shahidi S, et al. Spironolactone in chronic hemodialysis patients improves cardiac function. Saudi J Kidney Dis Transplant. 2009;20:392–397.
   PubMedGoogle Scholar
• Vukusich A, Kunstmann S, Varela C, et al. A randomized, double-blind, placebo-controlled trial of spironolactone on carotid intima-media thickness in nondiabetic hemodialysis patients. Clin J Am Soc Nephrol. 2010;5:1380–1387.
   PubMed Web of Science ®Google Scholar
• Feniman-De-Stefano GM, Zanati-Basan SG, De Stefano LM, et al. Spironolactone is secure and reduces left ventricular hypertrophy in hemodialysis patients. Therapeut Adv Cardiovasc Dis. 2015;9:158–167.
   PubMedGoogle Scholar
• Walsh M, Manns B, Garg AX, et al. The safety of eplerenone in hemodialysis patients: A noninferiority randomized controlled trial. Clin J Am Soc Nephrol. 2015;10:1602–1608.
   PubMed Web of Science ®Google Scholar
• Saudan P, Mach F, Perneger T, et al. Safety of low-dose spironolactone administration in chronic hemodialysis patients. Nephrol Dial Transplant. 2003;18:2359–2363.
   PubMed Web of Science ®Google Scholar
• Michea L, Vukusich A, Gonzalez M, Zehnder C, Marusic ET. Effect of spironolactone on K(+) homeostasis and ENaC expression in lymphocytes from chronic hemodialysis patients. Kidney Int. 2004;66:1647–1653.
   PubMed Web of Science ®Google Scholar
• Shavit L, Neykin D, Lifschitz M, Slotki I. Effect of eplerenone on blood pressure and the renin–angiotensin–aldosterone system in oligo-anuric chronic hemodialysis patients—A pilot study. Clin Nephrol. 2011;76:388–395.
   PubMed Web of Science ®Google Scholar
• Flevari P, Kalogeropoulou S, Drakou A, et al. Spironolactone improves endothelial and cardiac autonomic function in non heart failure hemodialysis patients. J Hypertens. 2013;31:1239–1244.
   PubMed Web of Science ®Google Scholar
• Hussain S, Dreyfus DE, Marcus RJ, Biederman RW, McGill RL. Is spironolactone safe for dialysis patients? Nephrol Dial Transplant. 2003;18:2364–2368.
   PubMed Web of Science ®Google Scholar
• Matsumoto Y, Kageyama S, Yakushigawa T, et al. Long-term low-dose spironolactone therapy is safe in oligoanuric hemodialysis patients. Cardiology. 2009;114:32–38.
   PubMed Web of Science ®Google Scholar
• Baker WL, White WB. Safety of mineralocorticoid receptor antagonists in patients receiving hemodialysis. Ann Pharmacother. 2012;46:889–894.
   PubMed Web of Science ®Google Scholar
• Chua D, Lo A, Lo C. Spironolactone use in heart failure patients with end-stage renal disease on hemodialysis: Is it safe? Clin Cardiol. 2010;33:604–608.
   PubMed Web of Science ®Google Scholar
• Ng KP, Arnold J, Sharif A, Gill P, Townend JN, Ferro CJ. Cardiovascular actions of mineralocorticoid receptor antagonists in patients with chronic kidney disease: A systematic review and meta-analysis of randomized trials. J Renin–Angiotensin–Aldosterone Syst. 2015;16:599–613.
   PubMed Web of Science ®Google Scholar
• Choi HY, Ha SK. Potassium balances in maintenance hemodialysis. Electrolyte Blood Press Blood. 2013;11:9–16.
   PubMedGoogle Scholar
• Hauben M, Reich L, Gerrits CM, Madigan D. Detection of spironolactone-associated hyperkalaemia following the Randomized Aldactone Evaluation Study (RALES). Drug Saf. 2007;30:1143–1149.
   PubMed Web of Science ®Google Scholar
• Beizer JL. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. Consult Pharmacist. 2005;20:148–149.
   PubMedGoogle Scholar
• Noori N, Kalantar-Zadeh K, Kovesdy CP, et al. Dietary potassium intake and mortality in long-term hemodialysis patients. Am J Kidney Dis. 2010;56:338–347.
   PubMed Web of Science ®Google Scholar
• Malik J, Tuka V, Mokrejsova M, Holaj R, Tesar V. Mechanisms of chronic heart failure development in end-stage renal disease patients on chronic hemodialysis. Physiol Res/Acad Sci Bohemoslov. 2009;58:613–621.
   Google Scholar
• Eschalier R, McMurray JJ, Swedberg K, et al. Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and/or worsening renal function: analyses of the EMPHASIS-HF study subgroups (Eplerenone in Mild Patients Hospitalization And Survival Study in Heart Failure). J Am Coll Cardiol. 2013;62:1585–1593.
   PubMed Web of Science ®Google Scholar
• Tsivgoulis G, Vemmos K, Papamichael C, et al. Common carotid artery intima-media thickness and the risk of stroke recurrence. Stroke. 2006;37:1913–1916.
   PubMed Web of Science ®Google Scholar
• Bots ML, Hoes AW, Koudstaal PJ, Hofman A, Grobbee DE. Common carotid intima-media thickness and risk of stroke and myocardial infarction: The Rotterdam Study. Circulation. 1997;96:1432–1437.
   PubMed Web of Science ®Google Scholar
• Lainscak M, Pelliccia F, Rosano G, et al. Safety profile of mineralocorticoid receptor antagonists: Spironolactone and eplerenone. Int J Cardiol. 2015;200:25–29.
   PubMed Web of Science ®Google Scholar
• Struthers A, Krum H, Williams GH. A comparison of the aldosterone-blocking agents eplerenone and spironolactone. Clin Cardiol. 2008;31:153–158.
   PubMed Web of Science ®Google Scholar
• Seferovic PM, Pelliccia F, Zivkovic I, et al. Mineralocorticoid receptor antagonists, a class beyond spironolactone—Focus on the special pharmacologic properties of eplerenone. Int J Cardiol. 2015;200:3–7.
   PubMed Web of Science ®Google Scholar
• Pitt B, Filippatos G, Gheorghiade M, et al. Rationale and design of ARTS: A randomized, double-blind study of BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease. Eur J Heart Fail. 2012;14:668–675.
   PubMed Web of Science ®Google Scholar
• Pitt B, Anker SD, Bohm M, et al. Rationale and design of MinerAlocorticoid Receptor antagonist Tolerability Study-Heart Failure (ARTS-HF): A randomized study of finerenone vs. eplerenone in patients who have worsening chronic heart failure with diabetes and/or chronic kidney disease. none. in who worsening heart with andor chronic disease. Eur J Heart Fail. 2015;17:224–232.
   PubMed Web of Science ®Google Scholar
• Pitt B, Kober L, Ponikowski P, et al. Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: A randomized, double-blind trial. Eur Heart J. 2013;34:2453–2463.
   PubMed Web of Science ®Google Scholar
• Hammer F, Krane V, Stork S, et al. Rationale and design of the Mineralocorticoid Receptor Antagonists in End-Stage Renal Disease Study (MiREnDa). Nephrol Dial Transplant. 2014;29:400–405.
   PubMed Web of Science ®Google Scholar
• University Hospital, Brest. ALdosterone Antagonist Chronic HEModialysis Interventional Survival Trial (ALCHEMIST). 2013. Available at: https://www.clinicaltrials.gov/ct2/show/NCT01848639. Accessed January 13, 2016.
   Google Scholar
• University of Pennsylvania. Safety and Cardiovascular Efficacy of Spironolactone in Dialysis-Dependent ESRD Trial (SPin-D). 2014. Available at: https://www.clinicaltrials.gov/ct2/show/NCT02285920.
   Google Scholar